ICBI UPDATE ON THE ROAD TO THE CURE

(“ICBII”), Reports on the Test Results of its Potential Alzheimer’s Drug

Neurodegenerative Alzheimer’s disease (AD) has become a global epidemic with more than 55 million individuals afflicted with the disease. US alone has 5.1 million Alzheimer’s patients. AD is the sixth-leading cause of death in the United States. It is the fifth-leading cause of death among those ages 65 and older and a leading cause of disability and poor health.

As the population of the United States ages, Alzheimer’s is becoming a more common cause of death. It is the only top 10 cause of death that cannot be prevented, cured or even slowed.

Although deaths from other major causes have decreased significantly, official records indicate that deaths from Alzheimer’s disease have increased significantly. Between 2000 and 2014, deaths from Alzheimer’s disease as recorded on death certificates increased 89 percent, while deaths from the number one cause of death (heart disease) decreased 14 percent.

Among people age 70, 61 percent of those with Alzheimer’s are expected to die before the age of 80 compared with 30 percent of people without Alzheimer’s… a rate twice as high.

There are currently no diagnostics and disease altering therapies available for AD and many other brain disorders because the blood-brain barrier (BBB) has stymied the entrance of most pharmaceuticals into the central nervous system (CNS). ICBII has developed BBB permeable technology, referred to as SMART Molecules (SMs) Technology that has been shown to work in animals by delivering drugs to their brain. To advance its technology to the next level where the drug reaching the CNS clears and/or reduces the pathological protein such as amyloid-plaque that is implicated in AD, ICBII’s scientists treated Alzheimer’s mice with its Amyloid-beta-SMART Molecule (Aβ-SM) for 12 weeks. The treated mice showed significantly (up to 60%) less amyloid-plaque in their brain than the untreated mice, demonstrating that ICBII SMs technology are not only capable of delivering drugs to the brain but also controlling the function of proteins involved in the disease process. These encouraging results are inspiring ICBII scientists and management to advance its SMs technology to treat human patients and the Company is diligently working to raise capital for scale up of its drugs for clinical trials.

ICBII Blood-Brain Barrier (BBB) Permeable SMs Technology vs Deep-Brain Implants to Deliver Drugs to the Central Nervous System

The following table outlines the merits and demerits of the two technologies:

 

ICBII SMs Technology Deep-Brain Implants
Mode of administration Simple intravenous injection Drilling a hole in the skull and using a thin needle to deliver drugs to the desired brain area.
Brain Drug Concentration The drug is distributed uniformly throughout the brain but since the SM does not bind to other non-target brain proteins, the potential of side effects is non-existent. Since most brain diseases are prion-like diseases, the uniform distribution of the SM is advantageous to treat such diseases. This technology has a potential to treat localized brain disease by delivering a bolus of drug into the effected brain region but may not be useful for treating Alzheimer’s, Parkinson’s, and Multiple System Atrophy (MSA) that tend to affect several brain areas.
Potential damage to the blood-brain barrier None Significant risk to damage the BBB and increasing the potential of blood-borne pathogens escaping into the brain
Potential Trauma to the brain None Edema from trauma and bleeding
Potential of Errant Cortex Stimulation and Seizers None Very high